Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

CorMedix Delivers Strong Q2, Expands DefenCath Footprint; Short Interest Signals Upside

Aug 13, 2026, 12:29 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Robust Q2 results, expanded DefenCath footprint, and a strong cash position enhance fundamentals and visibility. Elevated short interest could amplify moves around key catalysts (REZZAYO sNDA in Q3) and contract news, a common pattern in small-cap healthcare names.

AI summary

What happened, with direct paths to the underlying reporting

CorMedix posted robust Q2 results led by DefenCath-driven revenue and a strong cash position, with 2026 guidance reaffirmed. A multi-year DefenCath supply agreement expands the footprint to all five of the largest U.S. dialysis providers, and an sNDA for REZZAYO is anticipated in Q3. A high short interest adds a potential near-term upside catalyst.

CRMD Q2 revenue $101.9M; DefenCath $66.1M, Melinta $35.8M.
Net income $26.0M; adjusted EBITDA $58.7M.
Cash and short-term investments $256.7M as of June.
New multi-year DefenCath supply agreement expands to all top five U.S. dialysis providers.
Short interest 16.28M shares, >17 days to cover as of July 31.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

CorMedix Delivers Strong Q2, Expands DefenCath Footprint; Short Interest Signals Upside

CorMedix Gains on Strong Q2 Results, Triggering Short-Term Upside

Cormedix Reports Strong Q1, Raises 2026 Revenue Guidance and Pipeline Milestones

Positive Phase 3 Trial Results Boost CorMedix Shares

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations